Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
RadNet, Inc. to Present at the Jefferies Healthcare Services Conference on September 29, 2025
September 26, 2025 06:00 ET Â | Source: RadNet, Inc. LOS ANGELES, Sept.…
VivoPower Commences $29 Million Shareholder Loan Financing Retirement Plan
LONDON, July 07, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR)…